Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Shannon Dallas"'
Publikováno v:
Canadian Journal of Infectious Diseases, Vol 11, Iss 5, Pp 254-258 (2000)
OBJECTIVE: To evaluate the effect of the antimicrobial agent trimethoprim/sulphamethoxazole (TMP/SMX) on the pharmacokinetic properties of the antiretroviral drug zidovudine (ZDV).
Externí odkaz:
https://doaj.org/article/310dccd56ade43d38b6d1c8f2c523c87
Autor:
Shannon Dallas, Thomas Wilde, Avijit Ghosh, Jianyao Wang, Yawei Dong, Gaochao Tian, Daohong Liao, Xueliang Li, Lawrence Szewczuk, Peter King, David C. Evans, Yifan Shi, Kurtis E. Bachman, Javier Suarez, Beth Pietrak, James P. Edwards, Carlo Sensenhauser, Hao Chen, Vineet Pande, Peter J. Connolly, Karen DiLoreto, William G Bonnette, Shefali Patel, Zhuming Zhang
Publikováno v:
Journal of Medicinal Chemistry. 64:11570-11596
Selective cyclooxygenase (COX)-2 inhibitors have been extensively studied for colorectal cancer (CRC) chemoprevention. Celecoxib has been reported to reduce the incidence of colorectal adenomas and CRC but is also associated with an increased risk of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b02dbb581a1a9ad484e13ee726c09b
https://doi.org/10.1021/acs.jmedchem.1c00890
https://doi.org/10.1021/acs.jmedchem.1c00890
Autor:
David E. Coutant, David W. Boulton, Upendra P. Dahal, Antoine Deslandes, Christine Grimaldi, Joao N.S. Pereira, Carolina Säll, Hetal Sarvaiya, Hilmar Schiller, Guoying Tai, Kenichi Umehara, Yang Yuan, Shannon Dallas
Publikováno v:
Clinical pharmacology and therapeutics.
Typically, therapeutic proteins (TPs) have a low risk for eliciting meaningful drug interactions (DIs). However, there are select instances where TP drug interactions (TP-DIs) of clinical concern can occur. This white paper discusses the various type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff143ea497f2f1f7a99bae1fc026c1ca
https://pubmed.ncbi.nlm.nih.gov/36477720
https://pubmed.ncbi.nlm.nih.gov/36477720
Autor:
Heidi J. Einolf, Barry Jones, Phillip D. Yates, Theunis C. Goosen, Diane Ramsden, Conrad Fung, Y. Amy Siu, Niresh Hariparsad, Simon Wong, Liangfu Chen, Jairam Palamanda, George Zhang, Donald J. Tweedie, Shannon Dallas
Publikováno v:
Drug Metabolism and Disposition. 49:94-110
Translational and ADME Sciences Leadership Group Induction Working Group (IWG) presents an analysis on the time course for cytochrome P450 induction in primary human hepatocytes. Induction of CYP1A2, CYP2B6, and CYP3A4 was evaluated by seven IWG labo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa020936133a247e86ba65e02dc01b76
https://doi.org/10.1124/dmd.120.000055
https://doi.org/10.1124/dmd.120.000055
Autor:
Donald J. Tweedie, Robert L. Walsky, Diane Ramsden, Conrad Fung, Liangfu Chen, Michael A. Mohutsky, David B. Buckley, Theunis C. Goosen, Y. Amy Siu, Maria Fitzgerald, Shannon Dallas, George Zhang, Jane R. Kenny, Niresh Hariparsad, Heidi J. Einolf, Joshua G. Dekeyser
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 46(9)
The Innovation and Quality Induction Working Group presents an assessment of best practice for data interpretation of in vitro induction, specifically, response thresholds, variability, application of controls, and translation to clinical risk assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a363861f9fd5379ff3cfeccdf0985ed
https://pubmed.ncbi.nlm.nih.gov/29959133
https://pubmed.ncbi.nlm.nih.gov/29959133
Autor:
Y. Amy Siu, Jairam Palamanda, Robert L. Walsky, George Zhang, David B. Buckley, Michael A. Mohutsky, Donald J. Tweedie, Liangfu Chen, Magalie Pardon, Shannon Dallas, Suresh K. Balani, Diane Ramsden, Barry Jones, Heidi J. Einolf, Jane R. Kenny, Odette A. Fahmi, Michael Sinz, Niresh Hariparsad, Joshua G. Dekeyser
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 45(10)
The European Medicines Agency (EMA), the Pharmaceutical and Medical Devices Agency (PMDA), and the Food and Drug Administration (FDA) have issued guidelines for the conduct of drug-drug interaction studies. To examine the applicability of these regul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa706cdb57f6dcbd095aafbcf456d8b
https://pubmed.ncbi.nlm.nih.gov/28646080
https://pubmed.ncbi.nlm.nih.gov/28646080
Autor:
Shannon Dallas, Jose Silva, Xin Hong, Yinghua Qu, Rashidah Binte Sakban, N. Singh, Carlo Sensenhauser, Sylvia Zhao, Heng-Keang Lim, Hanry Yu, Michael McMillian, Lei Xia
Publikováno v:
Journal of Applied Toxicology. 36:320-329
Cytochrome P450 (CYP) induction is a key risk factor of clinical drug-drug interactions that has to be mitigated in the early phases of drug discovery. Three-dimensional (3D) cultures of hepatocytes in vitro have recently emerged as a potentially bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::260f81b504e4d08f88ecf9935798f29b
https://doi.org/10.1002/jat.3189
https://doi.org/10.1002/jat.3189
Autor:
Raymond Evers, Nico Scheer, Anja Rode, Laurent Salphati, Xiaoyan Chu, Robert A.B. van Waterschoot, Jodie Pang, Jashvant D. Unadkat, Jeevan Kunta, Liangfu Chen, Matthew G. Soars, Loic Laplanche, Shannon Dallas, Jocelyn Yabut, Alfred H. Schinkel, Mario Mezler, Bhagwat Prasad, Ethan G. Geier, Jonathan R Kehler, Donna Mamaril-Fishman
Publikováno v:
Drug Metabolism and Disposition. 42:1301-1313
Organic anion transporting polypeptide (Oatp) 1a/1b knockout and OATP1B1 and -1B3 humanized mouse models are promising tools for studying the roles of these transporters in drug disposition. Detailed characterization of these models will help to bett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::963514d091e7ee72a2f93a833f7cd334
https://doi.org/10.1124/dmd.114.057976
https://doi.org/10.1124/dmd.114.057976
Autor:
Jan Snoeys, Ellen Scheers, David C. Evans, Carlo Sensenhauser, Heng-Keang Lim, Laurent Leclercq, Peter Verboven, Shannon Dallas, Michael F. Kelley, Mark D. Johnson, Filip Cuyckens, Rao N.V.S. Mamidi
Aims Canagliflozin is a recently approved drug for use in the treatment of type 2 diabetes. The potential for canagliflozin to cause clinical drug-drug interactions (DDIs) was assessed. Methods DDI potential of canagliflozin was investigated using in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd2c9abf5fb872c233c8c45485ac3e9b
https://europepmc.org/articles/PMC5401984/
https://europepmc.org/articles/PMC5401984/
Publikováno v:
Drug Metabolism and Pharmacokinetics. 34:S52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::185534c0b698705b6c095337028d96c9
https://doi.org/10.1016/j.dmpk.2018.09.183
https://doi.org/10.1016/j.dmpk.2018.09.183